CoChat

Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy

Open access
Tripathi, Prem Prakash, Arami, Hamed, Banga, Ivneet, Gupta, Jalaj, Gandhi, Sonu · 2018 · Oncotarget
Cited by 130

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

// Prem Prakash Tripathi 1, 2 , Hamed Arami 3, 4 , Ivneet Banga 5 , Jalaj Gupta 6 and Sonu Gandhi 7 1 CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata, India 2 IICB-Translational Research Unit of Excellence, Kolkata, India 3 Molecular Imaging Program at Stanford (MIPS), The James H. Clark Center, Stanford University, Stanford, CA, USA 4 Department of Radiology, Stanford University, School of Medicine, Stanford, CA, USA 5 Department of Bioengineering, University of Texas, Arlington, TX, USA 6 Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany 7 DBT-National Institute of Animal Biotechnology (DBT-NIAB), Hyderabad, India Correspondence to: Sonu Gandhi, email: gandhi@niab.org.in Prem Prakash Tripathi, email: prem.tripathi@iicb.res.in Keywords: cell penetrating peptides; cancer targeting; therapy; diagnostic; imaging Received: September 07, 2018 Accepted: November 29, 2018 Published: December 14, 2018 ABSTRACT Delivery of imaging reagents and drugs to tumors is essential for cancer diagnosis and therapy. In addition to therapeutic and diagnostic functionalities, peptides have potential benefits such as biocompatibility, ease to synthesize, smaller size, by-passing off-target side effects, and achieving the beneficial effects with lower-administered dosages. A particular type of peptide known as cell penetrating peptides (CPP) have been predominantly studied during last twenty years as they are not only capable to translocate themselves across membranes but also allow carrier drugs to translocate across plasma membrane, by different mechanisms depending on the CPP. This is of great potential importance in drug delivery systems, as the ability to pass across membranes is crucial to many drug delivery systems. In spite of significant progress in design and application of CPP, more investigations are required to further improve their delivery to tumors, with reduced side-effect and enhanced therapeutic efficacy. In this review, we emphasis on current advancements in preclinical and clinical trials based on using CPP for more efficient delivery of anti-cancer drugs and imaging reagents to cancer tissues and individual cells associated with them. We discuss the evolution of the CPPs-based strategies for targeted delivery, their current status and strengths, along with summarizing the role of CPPs in targeted drug delivery. We also discuss some recently reported diagnostic applications of engineered protease-responsive substrates and activable imaging complexes. We highlight the recent clinical trial data by providing a road map for better design of the CPPs for future preclinical and clinical applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.26442

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 130

Metadata

Authors
Tripathi, P. P., Arami, H., Banga, I., Gupta, J., & Gandhi, S.
Venue
Oncotarget
Published
2018-12-14
Volume
9
Issue
98
Pages
37252-37267
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2905504720
Cited by
130
References
5
FWCI
4.32
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.